Published on March 19, 2010 at 9:12 AM
Synergy Pharmaceuticals, Inc. (OTC BB:SGYP), a developer of new drugs to
treat gastrointestinal disorders and diseases, announced today the
initiation of dosing in a Phase IIa clinical trial of SP-304 in patients
with chronic constipation (CC). This is a Phase IIa, randomized,
double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation
study in patients with chronic constipation. The objectives of the Phase
IIa clinical trial with SP-304 are to characterize the safety of SP-304
for 14 days in patients with CC and establish doses for the larger
planned Phase IIb trial in CC patients.
“SP-304 offers hope to the millions of patients suffering from CC and
other human gastrointestinal conditions, for which there are currently
limited treatment options”
“SP-304 offers hope to the millions of patients suffering from CC and
other human gastrointestinal conditions, for which there are currently
limited treatment options,” said Gary S. Jacob, Ph.D., President and CEO
of Synergy. “The initiation of this trial is another major milestone in
our development of this drug that we believe has the potential of
delivering higher efficacy and a better safety profile than any other
competitive product.”
Source Synergy Pharmaceuticals, Inc.